| Zhang, Yiping |
NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor |
|
|
| Recruiting | 2 | 200 | RoW | TQ-B3101 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Malignant Tumor | 03/21 | 09/21 | | |
NCT06166836: a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors |
|
|
| Recruiting | 1/2 | 140 | RoW | D1553, IN10018（Ifebemtinib）, BI 853520 | InxMed (Shanghai) Co., Ltd., InventisBio Co., Ltd | Solid Tumor | 12/25 | 12/26 | | |
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 183 | Japan, US, RoW | Glumetinib, SCC244 | Haihe Biopharma Co., Ltd. | C-Met Exon 14 Mutation | 10/23 | 12/23 | | |
NCT05492045: A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer |
|
|
| Terminated | 1/2 | 22 | RoW | D-1553, Other | InventisBio Co., Ltd | NSCLC | 06/24 | 06/24 | | |
NCT05543330: A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC |
|
|
| Not yet recruiting | 1/2 | 96 | RoW | M701 pleural infusion, Pleural drainage, Cisplatin pleural infusion | Wuhan YZY Biopharma Co., Ltd. | Malignant Pleural Effusions, NSCLC Stage IV | 06/24 | 12/24 | | |
NCT05552781: H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC |
|
|
| Recruiting | 1/2 | 76 | RoW | H002 capsule, H002 | RedCloud Bio, R&G Pharma Studies Co.,Ltd. | Non-small Cell Lung Cancer | 02/25 | 02/25 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT04448379: Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 1 | 48 | RoW | JMT101, Afatinib or Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 12/21 | 06/22 | | |
NCT03917043: APG-2449 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | APG-2449, APG-2449 Capsule | Ascentage Pharma Group Inc., Suzhou Yasheng Pharmaceutical Co., Ltd. | Advanced Solid Cancer, Non Small Cell Lung Cancer, Esophageal Cancer, Ovarian Cancer, Malignant Pleural Mesothelioma | 01/25 | 02/25 | | |
NCT04617314: A Study of RC108-ADC in Subjects with Advanced Malignant Solid Tumors |
|
|
| Active, not recruiting | 1 | 32 | RoW | RC108, RC108 for injection | RemeGen Co., Ltd. | Solid Tumor | 05/25 | 12/25 | | |
| Chen, Xiaozhong |
NCT04061278: A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma Patients |
|
|
| Recruiting | 3 | 246 | RoW | 4 cycles of Neoadjuvant Chemotherapy With Definitive Radiotherapy, 3 cycles of Neoadjuvant Chemotherapy With concurrent chemoradiotherapy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Nasopharyngeal Carcinoma, Neoadjuvant Chemotherapy | 06/22 | 12/22 | | |
IRCNPC, NCT03015727: Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 440 | RoW | Docetaxel, DOC, Cisplatin, DDP, IMRT/TOMO, Chemotherapy, concurrent chemotherapy | Zhejiang Cancer Hospital, Zhejiang Provincial People's Hospital, The Central Hospital of Lishui City, Jinhua Central Hospital, First Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Eastern Hospital, People's Hospital of Quzhou | Locally Advanced Nasopharyngeal Carcinoma | 12/22 | 12/24 | | |
NCT04974398: A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 278 | Canada, US, RoW | Penpulimab, cisplatin, gemcitabine, placebo | Akeso | Nasopharyngeal Carcinoma | 02/25 | 09/26 | | |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
NCT03907826: PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients |
|
|
| Recruiting | 3 | 212 | RoW | PD-1 blocking antibody, JS001, GP, IMRT | Sun Yat-sen University | Recurrent Nasopharyngeal Carcinoma | 12/25 | 12/28 | | |
NCT05340491: Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial |
|
|
| Recruiting | 3 | 212 | RoW | Toripalimab, JS001, Chemotherapy, GP, Intensity modulated radiotherapy, IMRT | Sun Yat-sen University | Nasopharyngeal Carcinoma | 12/24 | 12/27 | | |
NCT05780372: Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 474 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy | Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Chongqing University Cancer Hospital, Dongguan People's Hospital, LiuZhou People's Hospital | Nasopharyngeal Carcinoma, Radiotherapy; Complications | 05/25 | 05/28 | | |
NCT03678649: A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC |
|
|
| Recruiting | 2 | 180 | RoW | Capecitabine | Zhejiang Cancer Hospital | Head and Neck Neoplasms | 12/20 | 12/23 | | |
NCT03904225: Tegio Consolidation Therapy for NPC Patients With High Risk of Metastasis |
|
|
| Recruiting | 2 | 220 | RoW | Tegafur-Gimeracil-Oteracil | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 12/22 | 12/22 | | |
NCT05232552: Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 37 | RoW | Anlotinib hydrochloride, induction chemotherapy, IC, concurrent chemoradiation, CCRT | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 12/22 | 12/24 | | |
NCT04736810: A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal Carcinoma |
|
|
| Completed | 2 | 28 | RoW | AK105, Cisplatin, Gemcitabine, Anlotinib hydrochloride | Akeso, Akeso Tiancheng, Inc | Nasopharyngeal Carcinoma | 06/22 | 12/23 | | |
NCT06055816: Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 40 | RoW | Endostar and Envafolimab | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 09/24 | 06/28 | | |
NCT05813626: Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 89 | RoW | Toripalimab | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma | 10/24 | 10/27 | | |
NCT05024019: Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery |
|
|
| Not yet recruiting | 2 | 95 | RoW | Nimotuzumab | Eye & ENT Hospital of Fudan University | Head and Neck Squamous Cell Carcinoma | 08/25 | 08/25 | | |
| Recruiting | 1/2 | 114 | RoW | AK112, AK117, Carboplatin, Cisplatin, 5-Fluorouracil | Akeso | Advanced Malignant Tumors | 02/23 | 02/24 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT03657017: PET/MR in Locally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 150 | RoW | PET/MR | Zhejiang Cancer Hospital | Nasopharyngeal Carcinoma, PET/MR | 06/22 | 12/25 | | |
NCT05126160: Immune Score Based Radiomics in Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 494 | RoW | Immune Score Based Radiomics | Zhejiang Cancer Hospital, Renmin Hospital of Wuhan University, First Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Ningbo No. 1 Hospital | Nasopharyngeal Carcinoma | 10/22 | 12/27 | | |
| Chen, Xiao-Zhong |
DIAMOND, NCT04907370: PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 3 | 540 | RoW | PD-1 blocking antibody, PD-1 Blockade, Gemcitabine, GEM, Cisplatin (80mg/m2), DDP, Cisplatin (100mg/m2), Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd. | Nasopharyngeal Carcinoma | 05/25 | 05/27 | | |
PLATINUM, NCT03984357: Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 2 | 152 | RoW | PD-1 blocking antibody, PD-1 blockade, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Bristol-Myers Squibb | Nasopharyngeal Carcinoma | 04/24 | 03/26 | | |
| Yang, Haiyan |
NCT06285370: A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy |
|
|
| Recruiting | 4 | 20 | RoW | Mogamulizumab | Kyowa Kirin China Pharmaceutical Co., Ltd. | Cutaneous T-Cell Lymphoma | 10/25 | 01/26 | | |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Recruiting | 2 | 26 | RoW | Rituximab, chidamide, lenalidomde | Zhejiang Cancer Hospital | Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect, Chemotherapeutic Toxicity | 03/22 | 12/22 | | |
NCT06511895: AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) |
|
|
| Recruiting | 2 | 150 | RoW | AZD4205 | Dizal Pharmaceuticals | Peripheral T Cell Lymphoma | 05/25 | 12/26 | | |
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
| Active, not recruiting | 2 | 59 | RoW | CD19-targeted Chimeric Antigen Receptor (CAR) T Cells | Shanghai Ming Ju Biotechnology Co., Ltd. | Mantle Cell Lymphoma | 10/23 | 08/28 | | |
O-Gemox, NCT05381506: Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma |
|
|
| Not yet recruiting | 2 | 77 | RoW | Orelabrutinib and Gemox, O-Gemox | Sun Yat-sen University | DLBCL | 12/23 | 12/25 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Active, not recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
NCT04849351: Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma |
|
|
| Recruiting | 2 | 185 | RoW | HMPL-689, Phosphatidylinositol 3-kinase-δ inhibitor | Hutchison Medipharma Limited | Marginal Zone Lymphoma, Follicular Lymphoma | 04/24 | 12/24 | | |
NCT03936153: Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 2 | 170 | RoW | abexinostat | Xynomic Pharmaceuticals, Inc. | Diffuse Large B-cell Lymphoma (DLBCL) | 12/24 | 05/25 | | |
NCT05290090: ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL |
|
|
| Recruiting | 2 | 31 | RoW | Rituximab, Lenalidomide, Zanubrutinib and RCHOP, BGB-3111 | Zhejiang Cancer Hospital | Diffuse Large B Cell Lymphoma | 06/24 | 12/25 | | |
NCT06674096: RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL |
|
|
| Recruiting | 2 | 44 | RoW | RLC-CRCHOP | Zhejiang Cancer Hospital | Double-expressor Lymphoma | 12/29 | 06/30 | | |
NCT05992597: ZR2 Sequential Immunochemotherapy for Newly Treated MCL |
|
|
| Recruiting | 2 | 48 | RoW | ZR2 RDHAP | Zhejiang Cancer Hospital | Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma | 08/25 | 12/26 | | |
NCT06086197: A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL |
|
|
| Recruiting | 2 | 41 | RoW | Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin | Zhejiang Cancer Hospital | Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | 10/25 | 10/26 | | |
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853 |
|
|
| Recruiting | 1/2 | 254 | US, RoW | HH2853 Tablets | Haihe Biopharma Co., Ltd. | FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor | 12/25 | 12/25 | | |
NCT05155839: Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL) |
|
|
| Recruiting | 1 | 108 | RoW | MRG001 | Shanghai Miracogen Inc. | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | 10/22 | 10/23 | | |
| Cong, Luo |
NCT04446091: A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC) |
|
|
| Recruiting | 1/2 | 40 | RoW | Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.), Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+Irinotecan | Zhejiang Cancer Hospital | Colorectal Cancer | 07/21 | 07/22 | | |
